US stem cell clinics, patient safety, and the FDA

Scholarship on patients accessing unproven stem cell interventions is dominated by research addressing ‘stem cell tourism’ to such countries as China, India, Mexico, and the Ukraine. However, clinics marketing ‘adipose-derived mesenchymal stem cell treatments’ are proliferating across the USA. These...

Full description

Saved in:
Bibliographic Details
Published in:Trends in molecular medicine 2015-05, Vol.21 (5), p.271-273
Main Author: Turner, Leigh
Format: Article
Language:English
Subjects:
FDA
federal regulations
Humans
marketing
Pathology
Patient Safety
stem cell clinics
Stem Cell Research
Stem Cell Transplantation - adverse effects
Stem Cells - physiology
United States
United States Food and Drug Administration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Scholarship on patients accessing unproven stem cell interventions is dominated by research addressing ‘stem cell tourism’ to such countries as China, India, Mexico, and the Ukraine. However, clinics marketing ‘adipose-derived mesenchymal stem cell treatments’ are proliferating across the USA. These businesses typically claim to operate in compliance with federal regulations, but careful review of their commercial practices suggests that such clinics are marketing unapproved and noncompliant biological drugs.
ISSN:1471-4914
1471-499X
DOI:10.1016/j.molmed.2015.02.008